<DOC>
	<DOCNO>NCT00480350</DOCNO>
	<brief_summary>HIV infection grow problem Israel 4000 known patient either infected virus develop AIDS . Patients usually follow year develop increase viral load ( HIV-1 RNA ) CD4 + cell decline . At point , patient usually treat Highly Active , Anti-Retroviral Therapy ( HAART ) . The mainstay response treatment lower viral load increase CD4+ cell . Food supplement HIV patient give several study , controversial result . A meta-analysis publish recently [ 1 ] assess whether micronutrient supplement effective reduce morbidity mortality adult child HIV infection . They recommend support current WHO recommendation promote support adequate dietary intake micronutrient wherever possible . We expect enroll 140 subject randomize , double blind , placebo control study . Seventy subject enrol rice-supplement arm 70 subject control group , receive supplemental , flavor dextrose current medical treatment . The treatment duration 24 week follow-up 36 week enrollment . The target population HIV-1 infected individual may either anti-retroviral therapy therapy . Subjects must either CD4+ cell &lt; 500 cells/mm3 , HIV plasma RNA level &gt; 5000 copies/ml . The primary objective demonstrate efficacy food supplementation versus flavored-dextrose supplement respect increment patient CD4+ cell count baseline 24 week , virological response define lower plasma HIV-1 RNA immunologic response .</brief_summary>
	<brief_title>RiSolublesâ„¢ , Soluble Fraction Rice Bran HIV-Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Subjects document HIV1 infection Male female age &gt; 18 year old Subjects give informed consent Subjects may either receive receive antiretroviral therapy time enrollment Plasma HIV1 RNA high 5000 copies/ml OR Patient CD4+ cell count le 500 cells/mm3 Patients comply protocol requirement Patients incapable oral intake Patients allergic rice Pregnant breastfeed woman Active drug abuse , opinion investigator , expect interfere subject 's ability adhere study procedure Active , clinicallysignificant disease lifethreatening disease would compromise subject 's safety outcome study Any medical psychiatric condition , opinion investigator , could compromise subject 's safety adherence trial protocol Patients start antiHIV treatment within less 3 month inclusion study . However , patient change antiHIV medication initiate therapy 3 month inclusion eligible study . Patients know suffer diabetes mellitus Participation clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>HIV</keyword>
	<keyword>virological response</keyword>
	<keyword>CD4</keyword>
	<keyword>food supplement</keyword>
	<keyword>Human Immunodeficiency Virus</keyword>
	<keyword>Complementary Therapies</keyword>
</DOC>